| Cat.No. | Name | Information |
|---|---|---|
| M1937 | Dapagliflozin | Dapagliflozin (BMS-512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). |
| M30450 | Mizagliflozin | Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation. |
| M28119 | Licogliflozin | Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. |
| M21456 | Enavogliflozin | Enavogliflozin (DPW-16001), an antidiabetic compound, is a first class selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor with oral activity. |
| M20844 | Bexagliflozin (EGT1442) | Bexagliflozin (EGT1442, EGT-0001442, THR-1442) is a potent and selective SGLT2 inhibitor with an IC50 of 2 nM. |
| M20730 | KGA-2727 | KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models. |
| M10441 | Tofogliflozin (hydrate) | Tofogliflozin (CSG-452) hydrate is a potent and highly specific sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 value of 2.9 nM. |
| M8956 | Canagliflozin hemihydrate | Canagliflozin hemihydrate (JNJ-28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM. |
| M6272 | Ertugliflozin | Ertugliflozin (MK-8835, PF-04971729) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). |
| M6200 | Ipragliflozin L-Proline | Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyper-glycemic effect. |
| M5551 | Dapagliflozin ((2S)-1,2-propanediol, hydrate) | Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. |
| M5254 | Ipragliflozin | Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. |
| M5249 | Sotagliflozin | Sotagliflozin (LX-4211) is an orally active, first-in-class dual SGLT1/2 inhibitor with IC50s of 36 nM and 1.8 nM, respectively, and is used in studies related to type 1 diabetes and heart failure. |
| M4607 | Phloretin | Phloretin (NSC 407292; RJC 02792) is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). |
| M4606 | Phloridzin | Phloridzin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor. |
| M2667 | Empagliflozin | Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. |
| M2002 | Canagliflozin | Canagliflozin is a potent, selective sodium glucose co-transporter 2 inhibitor. |
| M56566 | Velagliflozin | Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. |
| M31405 | Tianagliflozin | Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes. |
| M31404 | JTT-662 | JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
